Dr. Pablo Ezequiel Pergola, MD

Dr. Pergola practices at Renal Associates, P.A. in San Antonio, Texas.

Dr. Pergola's NPI, 1902872765, was assigned on February 23, 2006. Dr. Pergola graduated from Univ Salvador- Fac Med in 1988. Dr. Pergola holds Texas license K4772.

Dr. Pergola's primary practice is Renal Associates, P.A., at 1123 N Main Ave, San Antonio, TX 78212 in Bexar County. The practice phone is (210) 614-1231.

Dr. Pergola's primary practice is Renal Associates, P.A. in San Antonio, Texas. The medical group on file is Renal Associates. Dmand AI also links Dr. Pergola to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pergola practices. Vendor and product names are available with a free account.

Nephrology is Dr. Pergola's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Pergola is board certified in nephrology by the American Board of Internal Medicine. Dr. Pergola is licensed in Texas.

Dmand AI lists acute kidney failure, chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Pergola treats.

CMS data shows 518 Medicare services from Dr. Pergola across 5 procedure codes in 2024, for 91 Medicare patients. Medicare paid $30,515 for them. Every service was in an office.

CMS counts 91 Medicare patients who saw Dr. Pergola in 2024. The largest group is 75 to 84, with 41 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 19% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pergola's median patient age at 74, with 54% women.

In 2024, Dr. Pergola wrote 1,838 Medicare Part D claims for 258 patients. 67% of them were for generic drugs. CMS names the drug for 1,481 of them, across 37 drugs with 11 or more claims each, at $662,640 in total drug cost. In 2023, CMS named 1,669 claims across 40 drugs.

Dr. Pergola accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 101 papers to Dr. Pergola, published from 2005 to 2024. 2021 was the busiest year, with 12. The most frequent topics are Renal Insufficiency, Chronic, Double-Blind Method and Glomerular Filtration Rate. Dr. Pergola has published most often in J Am Soc Nephrol. Dr. Pergola's most frequent co-authors are Glenn Matthew Chertow, MD, Geoffrey Allan Block, MD and Oscar Benavente, MD.

Dmand AI links Dr. Pergola to 14 clinical trials, 5 of them phase 2 studies. Conditions studied include Renal Insufficiency, Chronic, Renal Insufficiency and Polycystic Kidney, Autosomal Dominant. Biogen sponsors the most, 5. Open Payments lists research payments to Dr. Pergola that name 3 trials.

CMS Open Payments shows 382 general payments to Dr. Pergola from 41 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. Alexion Pharmaceuticals, Inc. paid the most, $25,973. It also lists 27 research payments totaling $211,809 from 2016 to 2025, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Pergola, most recently CMS Stage 1 EHR in 2013.

Dr. Pergola graduated from Univ Salvador- Fac Med in 1988.

Dr. Pergola is in network with 20 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.